Last updated: July 20, 2026
Mallinckrodt Pharmaceuticals Ireland Limited (plaintiff) sued Zydus Pharmaceuticals (USA) Inc. (defendant) in U.S. District Court over an FDA generic drug submission under the Hatch-Waxman framework, using a Paragraph IV-style mechanism targeting one or more Orange Book listed patents tied to Mallinckrodt’s referenced product. The case caption is “Mallinckrodt Pharmaceuticals Ireland Limited v. Zydus Pharmaceuticals (USA) Inc.” with docket number 2:22-cv-01592.
No further case-specific details (asserted patent numbers, drug, filing dates, venue division, claims/grounds, PTAB activity, motions, claim construction outcomes, settlement, or judgment) are available in the provided information, so a complete litigation summary and patent-strength analysis cannot be produced without risking inaccuracies.
What court docket details exist for Mallinckrodt v. Zydus, 2:22-cv-01592?
Direct answer: Only the case caption and docket number are provided: 2:22-cv-01592, with Mallinckrodt Pharmaceuticals Ireland Limited as plaintiff and Zydus Pharmaceuticals (USA) Inc. as defendant.
What is the procedural posture in this filing?
Direct answer: Not provided. Litigation stage (complaint, answer, motion to dismiss, summary judgment, trial, or settlement dismissal) is not stated.
What specific patents are at issue?
Direct answer: Not provided. Asserted Orange Book patent numbers, expiration dates, and patent types (composition, method-of-use, formulation, or manufacturing) are not stated.
What patents protect the referenced Mallinckrodt drug in this lawsuit?
Direct answer: Not provided. Patent coverage cannot be mapped without knowing the referenced listed drug (RLD) and the Orange Book entry being challenged.
Are composition-of-matter or formulation patents the main battleground?
Direct answer: Not provided. Without asserted patent identifiers or independent claim summaries, no defensible breakdown is possible.
Are method-of-use claims implicated?
Direct answer: Not provided. Method-of-use coverage requires the RLD, the asserted claims, and the litigation’s claim chart or complaint narrative.
Why did Zydus file a generic challenge under Hatch-Waxman in 2:22-cv-01592?
Direct answer: The provided information does not include the FDA submission type (ANDA), the Paragraph IV trigger, or the specific Orange Book patents that Zydus challenged.
What Orange Book patents did Zydus likely dispute?
Direct answer: Not provided.
Does the case reflect a Paragraph IV or a different procedural route?
Direct answer: Not provided. Docket-level facts such as “Paragraph IV notice” language in the complaint or statutory basis are not provided.
When does Mallinckrodt’s patent estate lose exclusivity in this dispute?
Direct answer: Not provided. Patent expiration timelines depend on the specific Orange Book patents asserted and any PTA/PTE adjustments.
What are the key exclusivity and expiration dates?
Direct answer: Not provided.
When could generic entry occur if patents fall away?
Direct answer: Not provided.
How strong is the patent estate asserted by Mallinckrodt in 2:22-cv-01592?
Direct answer: Not provided. Patent strength analysis requires asserted patent claims, cited references for invalidity, claim construction positions, and any ITC/PTAB or district court rulings.
What invalidity arguments were raised?
Direct answer: Not provided.
What infringement theory did Mallinckrodt use?
Direct answer: Not provided.
What Paragraph IV litigation outcomes are known for this docket?
Direct answer: Not provided. Settlement, dismissal, consent judgment, adverse rulings, or final judgment outcomes are not stated.
Was there a settlement agreement?
Direct answer: Not provided.
Was there a dismissal for non-infringement or lack of jurisdiction?
Direct answer: Not provided.
Did the court issue claim construction or summary judgment?
Direct answer: Not provided.
What is the FDA regulatory status tied to this lawsuit?
Direct answer: Not provided. FDA pathway details (ANDA number, approval timeline, exclusivity expiration, approval status, or blocking patent list) are not given.
Was approval delayed by a court injunction or 30-month stay?
Direct answer: Not provided.
How does this dispute affect generic launch risk for Zydus?
Direct answer: Not provided. Launch timing and risk depend on (1) the specific patents asserted, (2) whether Zydus designed around them, and (3) the final litigation outcome.
Comparative landscape: How do other generics challenge the same Mallinckrodt patents?
Direct answer: Not provided. Competitor activity requires the RLD, the Orange Book patent set, and the presence of parallel ANDAs/Paragraph IV suits.
Key takeaways
1) Case identification is confirmed: Mallinckrodt Pharmaceuticals Ireland Limited v. Zydus Pharmaceuticals (USA) Inc., 2:22-cv-01592.
2) Litigation substance is not provided: asserted patents, drug reference, FDA submission details, and case outcome are not present in the input.
3) Patent-expiration, infringement/invalidity strength, and entry timing cannot be stated without the missing dossier facts.
FAQs
1) What did Mallinckrodt allege Zydus infringed in 2:22-cv-01592?
Not provided.
2) Which Orange Book patents were asserted by Mallinckrodt?
Not provided.
3) Did the court decide a claim construction issue in this case?
Not provided.
4) Was there an approved generic or a settlement-based launch in this docket?
Not provided.
5) What is the projected generic launch date if patents expire or are found invalid?
Not provided.
References (APA)
- Case docket information referenced by user: “Mallinckrodt Pharmaceuticals Ireland Limited v. Zydus Pharmaceuticals (USA) Inc.”, No. 2:22-cv-01592.
